These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27131966)

  • 1. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Thiery E
    Urology; 2016 Aug; 94():57-63. PubMed ID: 27131966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
    Noblett K; Berg KC; Kan F; Siegel S
    Neurourol Urodyn; 2018 Jun; 37(5):1667-1671. PubMed ID: 29635879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
    Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
    Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men.
    Nguyen LN; Bartley J; Killinger KA; Gupta P; Lavin J; Khourdaji A; Gilleran J; Gaines N; Boura JA; Peters KM
    Int Urol Nephrol; 2018 May; 50(5):825-832. PubMed ID: 29532309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
    McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
    J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
    Chartier-Kastler E; Normand LL; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2022 Sep; 8(5):1399-1407. PubMed ID: 34334342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
    Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
    J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, multicenter, international study to explore the effect of three different amplitude settings in female subjects with urinary urge incontinence receiving interstim therapy.
    Elterman D; Ehlert M; De Ridder D; McCrery R; Pakzad M; Kaufman MR; Shah S; Margolis E; Bukkapatnam R; Johnson G; Zirpel L; Stolen K; Champs M; Goudelocke C
    Neurourol Urodyn; 2021 Mar; 40(3):920-928. PubMed ID: 33645864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
    Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
    Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence.
    Groenendijk PM; Lycklama à Nyeholt AA; Heesakkers JP; van Kerrebroeck PE; Hassouna MM; Gajewski JB; Cappellano F; Siegel SW; Fall M; Dijkema HE; Jonas U; van den Hombergh U;
    BJU Int; 2008 Feb; 101(3):325-9. PubMed ID: 18070199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence.
    Heesakkers JPFA; Toozs-Hobson P; Sutherland SE; Digesu A; Amundsen CL; McCrery RJ; De Wachter S; Kean ER; Martens F; Benson K; Ferrante KL; Cline KJ; Padron OF; Giusto L; Lane FL; Dmochowski RR
    Neurourol Urodyn; 2024 Sep; 43(7):1491-1503. PubMed ID: 38634481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study.
    van Kerrebroeck PE; van Voskuilen AC; Heesakkers JP; Lycklama á Nijholt AA; Siegel S; Jonas U; Fowler CJ; Fall M; Gajewski JB; Hassouna MM; Cappellano F; Elhilali MM; Milam DF; Das AK; Dijkema HE; van den Hombergh U
    J Urol; 2007 Nov; 178(5):2029-34. PubMed ID: 17869298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.